NEXT Financial Group Inc decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 40.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 495 shares of the biopharmaceutical company’s stock after selling 340 shares during the quarter. NEXT Financial Group Inc’s holdings in Regeneron Pharmaceuticals were worth $219,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Fieldpoint Private Securities LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $130,000. Sterling Investment Advisors Ltd. raised its holdings in Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 28 shares in the last quarter. FNY Partners Fund LP raised its holdings in Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 200 shares in the last quarter. IFP Advisors Inc raised its holdings in Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 96 shares in the last quarter. Finally, Virtu KCG Holdings LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $206,000. Hedge funds and other institutional investors own 66.51% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/11/22/regeneron-pharmaceuticals-inc-regn-stake-lessened-by-next-financial-group-inc.html.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded up $1.57 during mid-day trading on Wednesday, hitting $386.02. 58,814 shares of the stock traded hands, compared to its average volume of 900,146. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. Regeneron Pharmaceuticals, Inc. has a 12 month low of $340.09 and a 12 month high of $543.55. The stock has a market cap of $41,387.65, a price-to-earnings ratio of 33.35, a P/E/G ratio of 1.51 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same quarter last year, the business posted $3.13 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 23.0% compared to the same quarter last year. equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.

A number of equities analysts have recently issued reports on REGN shares. Leerink Swann reissued a “positive” rating and issued a $552.00 target price (down from $580.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Robert W. Baird raised Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a report on Friday, November 3rd. Piper Jaffray Companies reissued an “overweight” rating and issued a $557.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 1st. Zacks Investment Research cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Finally, Guggenheim reaffirmed a “buy” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $475.34.

In other news, SVP Robert E. Landry sold 427 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $493.43, for a total transaction of $210,694.61. Following the sale, the senior vice president now owns 9,099 shares in the company, valued at approximately $4,489,719.57. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Charles A. Baker sold 2,000 shares of the firm’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the sale, the director now owns 11,000 shares in the company, valued at approximately $4,950,000. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,779 shares of company stock valued at $2,248,467. 10.80% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.